Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02NJE
|
|||
| Former ID |
DIB001711
|
|||
| Drug Name |
PEK fusion protein vaccine
|
|||
| Indication | Cervical cancer [ICD-11: 2C77.0; ICD-9: 180] | Phase 1 | [1] | |
| Company |
Healthbanks biotech usa
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01880411) Phase I, Open-Label Study of the Safety, Tolerability, and Immunogenicity PEK Fusion Protein Vaccine. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.